Rachel Grossman, MD, of Tel Aviv Sourasky Medical Center, discusses the treatment landscape for patients with newly diagnosed glioblastoma. She focuses on treatments utilizing tumor treating fields, an antimitotic treatment.
Rachel Grossman, MD, of Tel Aviv Sourasky Medical Center, discusses the treatment landscape for patients with newly diagnosed glioblastoma. She focuses on treatments utilizing tumor treating fields (TTFields) (Optune), an antimitotic treatment.
TTFields is a local, noninvasive treatment modality that delivers electric fields to the tumor site at low intensity, Grossman says.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More